144 related articles for article (PubMed ID: 12719296)
21. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment.
Williams L; Frenneaux M
Europace; 2007 Sep; 9(9):817-22. PubMed ID: 17522079
[TBL] [Abstract][Full Text] [Related]
22. Hypertrophic Cardiomyopathy, Athlete's Heart, or Both: A Case of Hypertrophic Cardiomyopathy Regression.
Kebed KY; Bos JM; Anavekar NS; Mulvagh SL; Ackerman MJ; Ommen SR
Circ Cardiovasc Imaging; 2015 Jul; 8(7):e003312. PubMed ID: 26162782
[No Abstract] [Full Text] [Related]
23. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P
J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577
[TBL] [Abstract][Full Text] [Related]
24. Editorial comment: Operation and failure.
Ovadia M
Pacing Clin Electrophysiol; 2005 Apr; 28(4):301-3. PubMed ID: 15826263
[No Abstract] [Full Text] [Related]
25. The science of uncertainty and the art of probability: syncope and its consequences in hypertrophic cardiomyopathy.
Elliott P; McKenna W
Circulation; 2009 Apr; 119(13):1697-9. PubMed ID: 19349332
[No Abstract] [Full Text] [Related]
26. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
[TBL] [Abstract][Full Text] [Related]
27. Ten common questions about hypertrophic cardiomyopathy...and misconceptions.
Maron BJ
Cardiol Rev; 2005; 13(2):59-60. PubMed ID: 15705254
[No Abstract] [Full Text] [Related]
28. Risk assessment with cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.
Gosling OE; Bellenger N; Spurrell P
Heart; 2009 Nov; 95(22):1843. PubMed ID: 19875370
[No Abstract] [Full Text] [Related]
29. Implantable cardioverter defibrillators in children.
Chun TU; Collins KK; Dubin AM
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):561-71. PubMed ID: 15225115
[TBL] [Abstract][Full Text] [Related]
30. [On the work by S. Reith and H. G. Klues "Therapy and risk-stratification in hypertrophic cardiomyopathy", Z Kardiol 92: 283-293 (2003)].
Schwab J; Bareiter T; Bär I; Gottwik M
Z Kardiol; 2003 Sep; 92(9):763. PubMed ID: 14508595
[No Abstract] [Full Text] [Related]
31. Risk management in hypertrophic cardiomyopathy.
Grace AA; Brady PA; Shapiro LM
Lancet; 2001 Feb; 357(9254):407-8. PubMed ID: 11273054
[No Abstract] [Full Text] [Related]
32. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
33. [Implantable cardioverter defibrillators in pediatric patients: results in a series of 33 cases].
Tisserant A; Sadoul N; Kouakam C; Kacet S; Rey C; Chauvin M; Lévy J; Mabo P; Marçon F
Arch Mal Coeur Vaiss; 2006 May; 99(5):433-8. PubMed ID: 16802731
[TBL] [Abstract][Full Text] [Related]
34. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
35. [Interventional treatment in hypertrophic cardiomyopathy].
Gietzen FH; Schümmelfeder J; Neuser H; Brunn J; Schumacher B; Kerber S
Herz; 2005 Mar; 30(2):102-10. PubMed ID: 15875098
[TBL] [Abstract][Full Text] [Related]
36. Hypertrophic cardiomyopathy: risk factors for life and living benefits insurance.
Pokorski RJ
J Insur Med; 2002; 34(1):43-60. PubMed ID: 15303593
[TBL] [Abstract][Full Text] [Related]
37. Syncope and risk of sudden death in hypertrophic cardiomyopathy.
Spirito P; Autore C; Rapezzi C; Bernabò P; Badagliacca R; Maron MS; Bongioanni S; Coccolo F; Estes NA; Barillà CS; Biagini E; Quarta G; Conte MR; Bruzzi P; Maron BJ
Circulation; 2009 Apr; 119(13):1703-10. PubMed ID: 19307481
[TBL] [Abstract][Full Text] [Related]
38. The never ending story of risk stratification for sudden death in hypertrophic cardiomyopathy.
Christiaans I; Wilde AA
Am J Cardiol; 2011 Jun; 107(12):1871. PubMed ID: 21640227
[No Abstract] [Full Text] [Related]
39. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy.
Maron MS; Finley JJ; Bos JM; Hauser TH; Manning WJ; Haas TS; Lesser JR; Udelson JE; Ackerman MJ; Maron BJ
Circulation; 2008 Oct; 118(15):1541-9. PubMed ID: 18809796
[TBL] [Abstract][Full Text] [Related]
40. Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy.
Christiaans I; Lekanne dit Deprez RH; van Langen IM; Wilde AA
Heart Rhythm; 2009 Sep; 6(9):1366-9. PubMed ID: 19539541
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
